Mayne Pharma Informs Shareholders of Generic Drugs Underperformance

Mayne pharma

Australia based Mayne Pharma had to make a tough announcement to shareholders this past week. The company acquired 42 generic drugs from Teva and Allergan in 2016, and those drugs are no meeting 2017 sales guidance. Mayne Pharma attributed the poor performance to a “tough pricing deflation cycle” in the US generics market.

Read the source article at FiercePharma

About the Author

Related Posts

Leave a Reply